NCT02593045View on ClinicalTrials.gov

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Cutaneous T-Cell Lymphoma
Interventions
BIOLOGICAL

IPH4102

Trial Locations (5)

75010

Hôpital Saint-Louis, Paris

Unknown

Stanford Cancer Center, Stanford

Ohio State University, Columbus

Leiden University Medical Center, Leiden

Guy's Hospital, London

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY

NCT02593045 - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | Biotech Hunter | Biotech Hunter